Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zhou, Linghui  [Clear All Filters]
2024
Wang L, Lv Y, Zhou L, Wu S, Zhu Y, Fu S, Ding S, Hong R, Zhang M, Yu H, et al. Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol. 2024;13(1):28.
2023
Chen L, Ding S, Cheng Y, Zhou L, Yan J, Cheng Q, Jin A, Zhou X, Huang H, Hu Y. Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy. Eur J Haematol. 2023.
Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023.
Yang Y, Lan Z, Yan J, Tang Z, Zhou L, Jin D, Jin Q. Effect of intra-knee injection of autologous adipose stem cells or mesenchymal vascular components on short-term outcomes in patients with knee osteoarthritis: an updated meta-analysis of randomized controlled trials. Arthritis Res Ther. 2023;25(1):147.
Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107-e116.
Hu Y, Zu C, Zhang M, Wei G, Li W, Fu S, Hong R, Zhou L, Wu W, Cui J, et al. Safety and efficacy of CRISPR-based non-viral locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study. EClinicalMedicine. 2023;60:102010.
2022
Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, Zhang M, Zhao H, Ding S, Chang AH, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2022.